Advances in Early Detection, Pathophysiology, and Management of Mild Cognitive Impairment. Volume II

Building on the success of the Advances in Early Detection, Pathophysiology, and Management of Mild Cognitive Impairment, we are pleased to launch Volume II.Mild cognitive impairment (MCI) is recognized as an intermediate stage between normal cognitive aging and dementia, representing a critical opportunity for timely intervention. Despite its growing prevalence, the pathophysiological underpinnings, early detection strategies, and effective interventions for MCI remain areas of active investigation.The Volume II of this Research Topic aims to explore the multifaceted nature of MCI and to highlight innovative approaches to improve its detection, characterization, and management. A particular emphasis will be placed on biomarkers and multi-omics approaches for early detection, including genomic, transcriptomic, proteomic, and metabolomic strategies, as well as advances in neuroimaging and digital phenotyping that enable more precise and scalable identification of early cognitive changes.A central focus of this Topic is the exploration of the pathophysiological mechanisms underlying MCI, including neuroinflammation, vascular contributions, mitochondrial dysfunction, and synaptic alterations. In this context, we particularly encourage submissions providing mechanistic insights into neuroinflammation and neurodegeneration, leveraging cutting-edge methodologies such as single-cell omics, metabolomics, and advanced imaging techniques.In addition to basic science and early detection, this Research Topic invites contributions exploring intervention strategies, including both pharmacological and non-pharmacological approaches. Pharmacological studies may address disease-modifying therapies targeting underlying biological pathways, while non-pharmacological interventions may include cognitive training, lifestyle modifications (e.g., physical activity, nutrition, sleep), and psychosocial support. We also welcome translational and clinical implementation research, including clinical trials and real-world studies that evaluate the effectiveness, feasibility, and scalability of these interventions in diverse populations.Through this Research Topic, we seek to foster a comprehensive and up-to-date understanding of MCI, bridging basic, translational, and clinical research to inform best practices and policy recommendations. The ultimate goal is to enhance patient-centered care, improve prognostic accuracy, and reduce the burden of dementia worldwide by intervening at the earliest possible stage.Potential themes for contributions include (but are not limited to):o Biomarkers and multi-omics approaches for early detection of MCIo Advances in neuroimaging and digital phenotypingo Mechanistic insights into neuroinflammation and neurodegenerationo Pharmacological and non-pharmacological intervention strategiesThe following topics will also be considered but should be submitted to specific section of Dementia Care:o Longitudinal studies and progression to dementiao Health disparities and equitable MCI careo Lifestyle modifications and MCI risk reductiono Cognitive training and digital health interventionsWe look forward to receiving contributions from researchers, clinicians, and interdisciplinary teams working to advance the field of MCI research and care.The primary goal of this Research Topic is to consolidate and highlight cutting-edge advances in understanding, early detection, and management of mild cognitive impairment (MCI). By fostering interdisciplinary collaboration among researchers, clinicians, and healthcare professionals, we aim to bridge the gap between basic science and clinical practice.This collection will showcase innovative diagnostic tools, novel biomarkers, and interventions targeting underlying biological mechanisms. Ultimately, this Research Topic seeks to inform clinical decision-making and shape future research priorities, with the overarching aim of improving outcomes for individuals at risk of or living with MCI and reducing the global burden of dementia.We welcome all article types accepted by the journal that contribute to the early identification of MCI through novel biomarkers (genetic, metabolic, neuroimaging, and multi-omics approaches). Authors are encouraged to review the section scope prior to submission to ensure alignment.Submissions addressing the heterogeneity of MCI—including clinical subtypes, disease trajectories, and sex/gender differences—are strongly encouraged, particularly those incorporating longitudinal designs to elucidate progression to dementia.We also invite studies addressing disparities in MCI diagnosis and care, with a focus on the role of social determinants of health and access to care in shaping outcomes across diverse populations. Contributions that integrate personalized medicine, digital health, and interdisciplinary care models are particularly welcome.In addition, we encourage manuscripts focusing on translational and clinical implementation research, as well as those leveraging advanced neuroimaging, digital phenotyping, and multi-omics approaches to improve early detection, stratification, and intervention in MCI. Topic editors: Cristian Sandoval-Vásquez, Pablo Valdés-Badilla, Edgar Vásquez-Carrasco Source: https://www.frontiersin.org/research-topics/80186/advances-in-early-detection-pathophysiology-and-management-of-mild-cognitive-impairment-volume-ii